English

• 1 Oct, 2024
  Spago Nanomedical in new phase with full focus on the Tumorad program
• 27 Aug, 2024
  Spago Nanomedical’s Phase I/IIa study Tumorad-01 continues following successful treatment completion of first patient group
• 21 Aug, 2024
  Spago Nanomedical interim report January-June 2024
• 10 Jun, 2024
  Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB
• 31 May, 2024
  Spago Nanomedical announces outcome of the exercise of warrants series TO12
• 23 May, 2024
  Spago Nanomedical receives declarations of intent from the largest owner, board and management team regarding the exercise of TO12
• 20 May, 2024
  Spago Nanomedical provides an update on Tumorad-01 – trial proceeds as planned
• 17 May, 2024
  The exercise period for Spago Nanomedical’s warrants of series TO12 commences today
• 16 May, 2024
  Spago Nanomedical publishes the annual report for 2023
• 6 May, 2024
  NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)